Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics Inc (NQ: CGTX )

0.4825 +0.0108 (+2.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 212,343
Open 0.4800
Bid (Size) 0.4600 (1)
Ask (Size) 0.4900 (99)
Prev. Close 0.4717
Today's Range 0.4652 - 0.4900
52wk Range 0.3400 - 2.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-75.13%
-75.13%
1 Month
-7.30%
-7.30%
3 Month
-73.04%
-73.04%
6 Month
-75.88%
-75.88%
1 Year
-61.09%
-61.09%

More News

Read More
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Dow Edges Lower; Ventyx Biosciences Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
Via Benzinga
Exposures Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
Via InvestorPlace
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
Via Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
Via InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Via InvestorPlace
Nasdaq Gains 1%; McDonald's Posts Downbeat Results
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.